Abstract: A recombinant nucleic acid used for the production of a defective adenovirus containing an inserted sequence coding for a cytokine under the control of a promoter in the genomic sequence of the recombinant adenovirus. This recombinant adenovirus is useful in the preparation of anti-tumoral drugs which can be directly injected into the tumor of the host.

Abstract: The invention relates to the production of peptide epitopes common to a plurality of antigens of the same multigene family, said epitopes containing at least one common pentapeptide sequence preceded by three amino acids at the N-terminal end and optionally followed by one or two amino acids at the C-terminal end. The invention also relates to polynucleotides coding for said epitopes. Said peptides and polynucleotides can be especially used in anti-tumour immunotherapy.

Abstract: The present invention relates to the use of small interfering RNAs (siRNAs) for silencing gene expression in antigen-presenting cells such as dendritic cells, in particular for immunomodulatory purposes.

Abstract: The present invention concerns a use of a MHC class II ligand, such as CD4 and LAG-3, for the manufacture of a medicament for preventing or treating pathological conditions involving an antigen specific immune response, as well as the use of LAG-3 in cancer-immunotherapy. The invention also concerns a pharmaceutical composition comprising an effective amount of an antigen able to induce an antigen-specific immune response together with an effective amount of a MHC class II ligand wherein said MHC class II ligand is present as an adjuvant-like agent.

Abstract: The invention relates to derivatives corresponding to formula I: in which X is an alkyl-(CH2)n— chain with n=0, 1 or 2, or O or N, Z is an aromatic which may contain heteroatoms chosen from O, N or S, as substitutions for the carbon atoms constituting said aromatic ring, this ring being substituted or otherwise with Rb, Rb represents 1 to 3 substituents chosen from —OH, —OR, —COOH, —COOR, —COH, —COR, —NH2, —NH(R), —NH(R,R?), —SH, —SR and CN, Ra is H or —(CH2)n?—Y, with n?=0, 1, 2 or 3 and Y and —CH3, —COOH, —COOR, —CN, —OH, —OR, SR, or an aryl group optionally substituted with Rb, R and R? represent a linear or branched alkyl chain of 1 to 4 C, and their pharmaceutically acceptable salts. Application as active ingredient of medicaments inhibiting retrovirus integrases.

Abstract: The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of a TLR3 receptor by cancer cells.

Abstract: The invention provides a method of transferring in vivo a molecule into a striated muscle cell. More specifically, a method of the invention comprises contacting in vivo a striated muscle cell with a molecule, and electrically stimulating the muscle cell with one or more unipolar pulses of an electric field intensity ranging from 1 to 800 V/cm2. In one embodiment, the molecule is a nucleic acid encoding a protein of interest. For example, the invention provides methods of promoting angiogenesis and hemostasis.

Abstract: The present invention relates to a peptide compound which causes a tumor-specific T response, and which comprises a sequence of at least 8 consecutive amino acids of the peptide sequence encoded by a frame-shifted sequence of the iCE gene. The invention also relates to a pharmaceutical composition comprising said peptide compound and to the use of these compounds for manufacturing a medicinal product intended for treating cancer, in particular for treating solid tumors.

Abstract: Recombinant nucleic acid for use in the production of a defective adenovirus containing an inserted sequence coding for a cytokine under the control of a promoter in the genomic sequence of the recombinant adenovirus. Said recombinant adenovirus is useful in the preparation of anti-tumoral drugs capable of being directly injected into the tumor of the host.

Abstract: The invention concerns a method for identifying peptide compounds derived from hsp70, having at least one mutation relative to the hsp70 natural sequence, said compounds bringing about a response T specific of tumours, and the peptide compounds obtainable by said method. The invention also concerns the use of said peptide compounds for performing repeated immunization in a subject so as to interrupt immune tolerance for the corresponding natural (non-mutated) peptide. Said peptide compounds are useful for preparing a medicine designed in particular for treating cancer optionally in combination with any agent provoking tumour cell stress.

Abstract: The present invention relates to a process for activating natural killer cells comprising bringing NK cells into contact with dendritic cells in vitro, ex vivo or in vivo. The invention also relates to cell compositions comprising activated NK cells, NK cell-dendritic cell co-cultures or dendritic cells, and to their use to stimulate the cytolytic activity of NK cells or natural immunity in vivo. The invention also relates to a NK cell stimulation factor present in the dendritic cell membrane, and to triggering media and factor(s) for dendritic cells and to their use, either alone or in combination, to stimulate NK activity, in particular in vivo. The invention can be used to control NK cell activity in vitro, ex vivo or in vivo, in particular under pathological conditions.

Abstract: A recombinant nucleic acid used for the production of a defective adenovirus containing an inserted sequence coding for a cytokine under the control of a promoter in the genomic sequence of the recombinant adenovirus. This recombinant adenovirus is useful in the preparation of anti-tumoral drugs which can be directly injected into the tumor of the host.

Abstract: The invention relates to an antiviral agent for use in combination with an anticancer agent, for the treatment of cancer. Especially, the invention provides means for the treatment of non-virus-associated cancer.

Abstract: A pharmaceutical composition for the treatment, prevention or diagnosis of a tumoral pathology comprising an active agent which stabilizes an actin network of a cellular cytoskeleton.

Abstract: A molecule binding to a target including an EP motif having the following sequence: (X-(EP)n-Y-(EP)m-Z)p wherein X, Y and Z may be identical or different and include a sequence of 0 to 10 amino acids, identical or different, n and m are integers between 0 to 20, preferably between 3 to 10, with at least one of n or m being different from 0, and p is an integer between 1 and 10.

Abstract: The invention pertains to use of a vector of the type comprising a nonliquid hydrophilic core for the preparation of a medication intended for the treatment of cancers and/or viral diseases, the vector being combined in the medication with at least one substance other than an antigen capable of modulating the immune response.

Abstract: The invention relates to an antiviral agent for use in combination with an anticancer agent, for the treatment of cancer. Especially, the invention provides means for the treatment of non-virus-associated cancer.

Abstract: The object of the invention is a novel sensitization process for antigen-presenting cells, novel means for implementing the process and novel membrane vesicles possessing immunogenic potency. The invention relates in particular to texosomes (vesicles derived from tumor cells) and dexosomes (vesicles derived from dendritic cells loaded or not with antigens), and their use for the vectorization and presentation of antigens in vitro or in vivo as well as in methods or compositions for the treatment of cancers and infectious, parasitic or autoimmune diseases in particular.

Abstract: A process for detecting malignant transformation of cells involves detecting the overexpression of the products of the &bgr;3, &bgr;5, &bgr;8 and &bgr;9 genes, which encode the hCG&bgr; subunit, relative to their expression in nonmalignant cells. A kit for diagnosing an hCG- or an hCG fragment-secreting cancer includes an assembly of polypeptides covering at least a part of the primary sequence of hCG. The use of a polypeptide corresponding to at least one portion of the primary sequence of hCG for producing a composition useful in hCG- or hCG fragment-secreting cancer immunotherapy is also disclosed.

Abstract: Soluble polypeptide fraction consisting of all or part one of at least one of the four immunoglobulin-type extracellular LAG-3 protein domains (amino acids 1-159, 160-230 239, 240-330 and 331-412 of the SEQ ID NO:1 sequence) or consisting of one peptide sequence derived from these domains by replacement, addition or deletion of one or more amino acids. The fraction of the invention has a specificity at least equal to that of LAG-3 in relation to its ligand.